文献速递血栓与止血

新型嵌合激活肽工程化因子X作为血友病旁路剂的理性设计

Rational design of a novel engineered factor X with chimeric activation peptide as bypassing agent for hemophilia.
PubMed 文献 · J Thromb Haemost · 2026-05-08

本研究开发了一种含FIX来源嵌合激活肽的人因子X变体(FXBP4b/4c),旨在绕过FVIII或FIX缺乏。功能实验显示,FXBP4b在HA和HB血浆中有效纠正凝血时间,在凝血酶生成实验中优于野生型FX,并与无B域FVIII和FIX活性相当或更优;FXBP4b还能显著缩短高滴度抑制物患者血浆的凝血时间。

要点

  • FXBP4b在HA和HB血浆中有效纠正凝血时间并恢复凝血酶生成。
  • FXBP4b活性与无B域FVIII和FIX相当或更优。
  • FXBP4b可缩短高滴度抗FVIII或抗FIX抑制物患者血浆的凝血时间。

核心结论

  • FXBP4b是一种有前景的多用途旁路剂,能在包括存在抑制物的多种血友病情境下维持凝血,并保持有利的激活特性。

研究设计与样本

  • 研究设计为工程化变体的表达、纯化及功能学评价,包括在HA和HB患者含抑制物血浆中的检测。

主要发现

  • FXBP4b和FXBP4c在生理浓度下有效纠正HA和HB血浆的凝血时间,而野生型FX无此效果。
  • FXBP4b和FXBP4c通过外源性tenase复合物或罗素蝰蛇毒X激活得以保留,而内源性激活途径受损,从而有利于其选择性剂量依赖性FXIa激活。
  • 在凝血酶生成实验中,FXBP4b-c恢复了FX缺乏血浆的凝血酶生成峰值和内源性凝血酶潜能。
  • FXBP4b在HA和HB血浆中优于野生型FX,与无B域FVIII和FIX相比活性相当或更优。
  • FXBP4b显著缩短高滴度抗FVIII或抗FIX抑制物患者血浆的凝血时间,疗效与成熟旁路剂相当。

临床怎么用

  • FXBP4b可作为潜在旁路剂用于血友病A和B患者,尤其存在高滴度抑制物时,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While replacement therapy in hemophilia (H)A and B (HB) has provided remarkable improvements, the development of neutralizing antibodies remains a significant complication, with rational engineering of bypassing (BP) molecules being a relevant issue. OBJECTIVES: This study developed a human factor (F)X variant containing a FIX-derived chimeric activation peptide (AP) driving FVIII or FIX deficiency bypass. METHODS: Engineered variants were expressed and purified, and activation/activity properties were evaluated through functional assays, also in plasma with inhibitors from patients with HA and HB. RESULTS: After screening a panel of recombinant variants, the most promising were purified for functional characterization. Unlike wild-type FX (FXWT), the BP variants FXBP4b and FXBP4c at physiological concentrations effectively normalized the clotting time in HA and HB plasma. Chromogenic assays confirmed that both variants preserved activation via the extrinsic tenase complex or by Russell viper venom X, while the intrinsic activation pathway was impaired, thus favoring their selective dose-dependent FXIa activation. In thrombin generation assays, FXBP4b-c restored the peak and the endogenous thrombin potential in FX-deficient plasma. Remarkably, the FXBP4b outperformed FXWT in HA and HB plasma and showed a comparable or superior activity in comparison with B-domainless FVIII and FIX. Notably, FXBP4b significantly shortened the clotting time in plasma from patients with high-titer anti-FVIII or anti-FIX inhibitory antibodies, with efficacy levels comparable with those of well-established BP agents. CONCLUSION: These results support FXBP4b as a promising and versatile BP agent able to sustain coagulation across multiple hemophilic contexts including inhibitors presence, while maintaining favorable activation profiles.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Tarantino R, Bunce MW, Tonetto E, et al. Rational design of a novel engineered factor X with chimeric activation peptide as bypassing agent for hemophilia. J Thromb Haemost. 2026. PMID: 42107708. doi:10.1016/j.jtha.2026.04.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。